Juergen Koessler

Summary

Country: Germany

Publications

  1. ncbi Evaluation of the new INNOVANCE® PFA P2Y cartridge in patients with impaired primary haemostasis
    Juergen Koessler
    Institut fuer Klinische Biochemie und Pathobiochemie Zentrallabor, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
    Platelets 23:571-8. 2012
  2. ncbi [Anticoagulants of primary haemostasis]
    J Kössler
    Institut für Klinische Biochemie und Pathobiochemie, Zentrallabor mit Gerinnungsambulanz, Universitatsklinikum Wurzburg, Josef Schneider Str 2, 97080 Wurzburg
    Hamostaseologie 29:274-8. 2009
  3. ncbi The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition
    Juergen Koessler
    Institut fuer Klinische Biochemie und Pathobiochemie mit Zentrallabor, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
    Platelets 22:20-7. 2011
  4. ncbi Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system
    Anna L Kobsar
    Institute of Clinical Biochemistry and Pathobiochemistry Central Laboratory, University Clinic Wuerzburg, Wuerzburg, Germany
    Platelets 21:112-6. 2010
  5. ncbi The thrombin inhibitors hirudin and Refludan(®) activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets
    Anna Kobsar
    Institut fuer Klinische Biochemie und Pathobiochemie Zentrallabor, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
    Thromb Haemost 107:521-9. 2012

Collaborators

Detail Information

Publications5

  1. ncbi Evaluation of the new INNOVANCE® PFA P2Y cartridge in patients with impaired primary haemostasis
    Juergen Koessler
    Institut fuer Klinische Biochemie und Pathobiochemie Zentrallabor, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
    Platelets 23:571-8. 2012
    ..As the main conclusion, it must be taken into account that low von Willebrand factor activity can significantly influence the CTs of the P2Y cartridge when using it for the monitoring of antiplatelet therapy...
  2. ncbi [Anticoagulants of primary haemostasis]
    J Kössler
    Institut für Klinische Biochemie und Pathobiochemie, Zentrallabor mit Gerinnungsambulanz, Universitatsklinikum Wurzburg, Josef Schneider Str 2, 97080 Wurzburg
    Hamostaseologie 29:274-8. 2009
    ..Results from recent experimental studies could lead to new strategies for antiplatelet therapy (like inhibition of GP Ib receptor, GP VI receptor, platelet-leukocyte interaction, factor XII and others) in the future...
  3. ncbi The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition
    Juergen Koessler
    Institut fuer Klinische Biochemie und Pathobiochemie mit Zentrallabor, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
    Platelets 22:20-7. 2011
    ..Its predictive value for risk assessment of thromboembolic events, e.g. after coronary stent implantation, needs to be evaluated in clinical trials...
  4. ncbi Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system
    Anna L Kobsar
    Institute of Clinical Biochemistry and Pathobiochemistry Central Laboratory, University Clinic Wuerzburg, Wuerzburg, Germany
    Platelets 21:112-6. 2010
    ..Future studies should now evaluate whether this modified PFA-100 system, like the VASP assay, is a reliable test system for monitoring P2Y(12) receptor inhibition under clinical conditions...
  5. ncbi The thrombin inhibitors hirudin and Refludan(®) activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets
    Anna Kobsar
    Institut fuer Klinische Biochemie und Pathobiochemie Zentrallabor, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
    Thromb Haemost 107:521-9. 2012
    ....